Source: PharmaTimes
Area: News
PharmaTimes reports that the Australian regulatory authority (the Therapeutic Goods Administration - TGA) has approved EYLEA® (aflibercept) injection for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD) at a recommended dose of 2 milligrams via intravitreal injection per month for three consecutive months, followed by 2 milligrams via intravitreal injection every two months. According to PharmaTimes, the company plan to launch the drug in Australia in the second half of 2012.
A marketing authorisation application for aflibercept for the treatment of wet AMD was submitted to the European Medicines Agency in June 2011. Please see previous NeLM news item link below.
Daily Archives: 2012/03/09
Managing Glaucoma – Home Measurements Of Eye Pressure In Children Effective
Large changes in intraocular pressure (IOP), also known as the pressure within the eye, in patients with glaucoma, tends to be associated with a progression of the disease that can result in permanent damage to a person's optic nerve and their vision...
Infrared optical head tracker can help diagnose ocular torticollis
Wii remotes are not all about fun and games. Scientists can use them to assess and diagnose children with an abnormal head position caused by eye diseases. As described in a recent Investigative Ophthalmology & Visual Science article, researchers developed a low-cost digital head posture measuring device with Nintendo Wiimotes to help diagnose this condition, medically called ocular torticollis.
How A Bacterial Pathogen Breaks Down Barriers To Enter And Infect Cells
Scientists from the Schepens Eye Research Institute, a subsidiary of Mass. Eye and Ear and affiliate of Harvard Medical School, have found for the first time that a bacterial pathogen can literally mow down protective molecules, known as mucins, on mucus membranes to enter and infect a part of the body...
Glaucoma Characterized In New Research As A Neurologic Disorder Rather Than Eye Disease
A new paradigm to explain glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of glaucoma solely as an eye disease...
Glaucoma Management In Children May Be Improved By Home Measurement Of Eye Pressure
Measurement of pressure within the eye, or intraocular pressure (IOP), is known to fluctuate throughout the day, and wide swings in patients with glaucoma are believed to be related to the progression of the disease, which can cause permanent damage to the optic nerve and vision. The clinical assessment of IOP, however, has been restricted to office visits during daytime hours...
Genetically modified pig may hold keys to develop treatments for RP
A newly developed, genetically modified pig may hold the keys to the development of improved treatments and possibly even a cure for retinitis pigmentosa (RP), the most common inherited retinal disease in the United States.
Avedro submits VibeX/KXL System NDA with FDA to treat keratoconus, corneal ectasia
Avedro, Inc. announced today that the Company submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for its VibeX (riboflavin ophthalmic solution) /KXL System for the treatment of keratoconus and corneal ectasia following refractive surgery.
Subscribe
